Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Sequenom jumps on 1Q13 revenues

Sequenom Inc. (NASDAQ:SGNM) gained $0.47 (13%) to $4.04 on

Read the full 96 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE